Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03 2020 - 4:05PM
Business Wire
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical
company focused on the development and commercialization of
therapeutics for people living with kidney disease, granted six
newly-hired employees options to purchase an aggregate of 113,450
shares of Akebia’s common stock on December 31, 2019, as
inducements material to each such employee’s entering into
employment with Akebia. The options were granted in accordance with
Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $6.32 per share, which is
equal to the closing price of Akebia’s common stock on the grant
date. Each stock option vests over four years, with 25% of the
shares vesting on the first anniversary of the grant date and the
remaining 75% of shares vesting quarterly thereafter, in each case,
subject to the new employee’s continued service with the company.
Each stock option has a 10-year term and is subject to the terms
and conditions of the company’s Inducement Award Program and a
stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated
biopharmaceutical company focused on the development and
commercialization of therapeutics for people living with kidney
disease. The company was founded in 2007 and is headquartered in
Cambridge, Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part of this
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200103005299/en/
Kristen K. Sheppard, Esq. ir@akebia.com
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2023 to Apr 2024